Revenue volatility remains a primary concern, with gross margins fluctuating significantly between 14.9% and 42.7% over the last ten quarters due to an unstable mix of healthcare staffing and digital health services.
| Sales/Revenue | 7.64M | 7.23M | 7.98M | 5.52M | 5.62M | 1.41M | 0 |
| Revenue Growth % | -5.51% | -9.47% | 44.73% | -1.83% | 298.43% | - | - |
| Cost of Goods Sold | 5.1M | 4.74M | 6.33M | 4.11M | 4.56M | 979.62K | 0 |
| COGS % of Revenue | - | 65.57% | 79.29% | 74.46% | 81.1% | 69.48% | - |
| Gross Profit | 2.54M | 2.49M | 1.65M | 1.41M | 1.06M | 430.35K | 0 |
| Gross Margin % | 33.2% | 34.43% | 20.71% | 25.54% | 18.9% | 30.52% | - |
| Gross Profit Growth % | - | 50.5% | 17.35% | 32.66% | 146.72% | - | - |
| Operating Expenses | 2.78M | 3.39M | 5.42M | 4.3M | 3.15M | 433.63K | 4.27K |
| OpEx % of Revenue | - | 46.94% | 67.88% | 77.96% | 56.1% | 30.75% | - |
| Selling, General & Admin | 2.17M | 3.3M | 1.45M | 4.01M | 3.11M | 416.01K | 4.27K |
| SG&A % of Revenue | - | 45.72% | 18.11% | 72.66% | 55.29% | 29.5% | - |
| Research & Development | 37.59K | 67.84K | 585.15K | 240.05K | 0 | 0 | 0 |
| R&D % of Revenue | - | 0.94% | 7.33% | 4.35% | - | - | - |
| Other Operating Expenses | 571.68K | 20.47K | 3.39M | 52.14K | 45.59K | 17.63K | 0 |
| Operating Income | -240.01K | -904.32K | -3.76M | -2.89M | -2.09M | -3.28K | -4.27K |
| Operating Margin % | -3.14% | -12.51% | -47.17% | -52.36% | -37.2% | -0.23% | - |
| Operating Income Growth % | - | 75.98% | -30.38% | -38.18% | -63610.21% | 23.13% | - |
| EBITDA | -226.58K | -883.86K | -3.7M | -2.84M | -2.07M | -3.07K | -4.27K |
| EBITDA Margin % | -2.97% | -12.23% | -46.38% | -51.47% | -36.93% | -0.22% | - |
| EBITDA Growth % | 91.72% | 76.13% | -30.41% | -36.82% | -67418.58% | 27.98% | - |
| D&A (Non-Cash Add-back) | 13.43K | 20.47K | 62.74K | 48.77K | 14.85K | 207 | 0 |
| EBIT | -230.32K | -904.32K | -3.74M | -2.88M | -2.09M | -3.28K | -4.27K |
| Net Interest Income | 56.92K | 7.99K | 5.65K | -50.74K | -28.47K | 0 | 0 |
| Interest Income | 69.42K | 21.26K | 21.25K | 2.94K | 63 | 0 | 0 |
| Interest Expense | 12.5K | 13.27K | 15.6K | 53.69K | 28.53K | 0 | 0 |
| Other Income/Expense | 56.92K | 7.99K | 5.65K | -50.74K | -28.47K | 0 | 0 |
| Pretax Income | -183.09K | -896.33K | -3.76M | -2.94M | -2.12M | -3.28K | -4.27K |
| Pretax Margin % | -2.4% | -12.4% | -47.1% | -53.28% | -37.71% | -0.23% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -183.09K | -896.33K | -3.76M | -2.94M | -2.12M | -3.28K | -4.27K |
| Net Margin % | -2.4% | -12.4% | -47.1% | -53.28% | -37.71% | -0.23% | - |
| Net Income Growth % | 93.42% | 76.16% | -27.94% | -38.72% | -64478.2% | 23.13% | - |
| Net Income (Continuing) | -183.09K | -896.33K | -3.76M | -2.94M | -2.12M | -3.28K | -4.27K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.01 | -0.08 | -0.52 | -0.60 | -0.29 | -0.00 | -0.00 |
| EPS Growth % | 95.84% | 85.46% | 13.33% | -106.9% | - | - | - |
| EPS (Basic) | - | -0.08 | -0.52 | -0.60 | -0.36 | -0.00 | -0.00 |
| Diluted Shares Outstanding | 12.78M | 11.85M | 7.26M | 4.88M | 7.28M | 7.28M | 5.98M |
| Basic Shares Outstanding | 11.94M | 11.85M | 7.26M | 4.88M | 5.86M | 7.28M | 5.98M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Liquidity and contract concentration
As indicated by the quarterly income statements, SYRA's revenue trajectory remains highly inconsistent, with the most recent period showing a 22.4% growth rate following a series of double-digit contractions, suggesting that the company's reliance on project-based government contracts creates significant top-line lumpiness for investors.
The erratic revenue performance highlights the difficulty in transitioning from transactional staffing placements to a more predictable, recurring digital health model. Investors should monitor whether the recent growth spike represents a sustainable shift in contract volume or merely the timing of specific, non-recurring government project completions.
Based on reported financial data, SYRA's gross margin has fluctuated significantly between 14.9% and 42.7% over the last ten quarters, reflecting the inherent volatility of balancing low-margin healthcare staffing services against the company's higher-margin, yet currently under-scaled, digital health and population health analytics offerings.
The wide variance in gross profitability suggests that the company lacks consistent pricing power and remains highly susceptible to shifts in the underlying service mix. Sustained margin expansion appears unlikely until the Syrenity platform achieves sufficient scale to offset the variable labor costs associated with the staffing segment.
According to the provided income statement history, SYRA has struggled to demonstrate positive operating leverage, as SG&A expenses frequently exceed gross profit, resulting in persistent operating losses that indicate the current corporate overhead is disproportionate to the company's limited revenue base.
The inability to scale operating income faster than gross profit suggests that the company's infrastructure is currently too heavy for its current revenue level. Unless management can significantly reduce SG&A intensity, the path to operational break-even remains obscured by the high costs of maintaining its current service footprint.
As reported in financial filings, SYRA's net income has remained largely negative throughout the observed period, with stock-based compensation and R&D investments further pressuring the bottom line, which warrants caution regarding the company's ability to generate sustainable shareholder value without external capital infusions.
The consistent net losses suggest that the company is currently in a cash-burning phase, prioritizing growth and platform development over immediate profitability. Investors should scrutinize the capitalization of software development costs, as these accounting choices may be masking the true extent of the company's ongoing operational cash burn.
Based on the provided financial snapshot, the most significant risk to the investment thesis is the company's limited cash position of $1.6M relative to its ongoing negative net margins, which suggests a high probability of dilutive financing events in the near term to sustain operations.
Short-sellers would likely focus on the company's inability to achieve consistent profitability despite its pivot toward digital health. The reliance on a small number of government contracts in a single geographic region creates a binary risk profile that could lead to rapid deterioration if key renewals are missed.
Quick answers to the most common questions about buying SYRA stock.
For fiscal year 2025, Syra Health Corp. Class A Common Stock (SYRA) reported total revenue of $7.2M.
Syra Health Corp. Class A Common Stock (SYRA) reported a net loss of $0.9M for the fiscal year ending 2025.
Syra Health Corp. Class A Common Stock (SYRA) reported an operating income of $-0.9M, resulting in an operating profit margin of -12.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Syra Health Corp. Class A Common Stock (SYRA) generated $2.5M in gross profit for the year, representing a gross profit margin of 34.4%. This demonstrates the company's core pricing power and production efficiency.